|
|
|
|
2D-Echo Test |
|
|
|
5-Hydroxyindoleacetic acid (5 HIAA) Test |
2-7 mg/24 h |
10.5-36.6 µmol/24 h |
|
|
|
|
|
Angiotensin-Converting Enzyme (ACE) Test |
8 - 53 microliters |
|
|
|
|
|
|
Acetaminophen Level Test |
Therapeutic level: 10-25 mcg/mL |
Toxic level: >200 mcg/mL |
|
|
|
|
|
AChR Antibody Test |
< or =0.02 nmol/L |
|
|
|
|
|
|
Acid-Fast Bacillus (AFB) Culture |
A positive culture is seen in cases of Tuberculosis |
|
|
|
|
|
ACTH stimulation Test |
> 18 - 20 mcg/dL |
|
|
|
|
|
|
Activated Clotting Time |
80 to 160 seconds |
|
|
|
|
|
|
Adenosine deaminase (ADA) Test |
< 40U/L |
|
|
|
|
|
|
Aldolase Test |
1 to 7.5 units per liter |
|
|
|
|
|
|
Aldosterone Test |
0-30 days |
17-154 ng/Dl |
|
|
31 days-11 months |
6.5-86 ng/dL |
|
|
1-10 years |
< =40 ng/dL (supine) |
|
|
|
< =124 ng/dL (upright) |
|
|
> =11 years |
< =21 ng/dL (a.m. peripheral vein specimen) |
|
|
|
|
Alkaline Phosphatase (ALP) Test |
20–140 units per liter (U/L). |
|
|
|
|
|
|
Allergy Blood Testing |
Total IgE < 81 kU/L |
|
|
|
|
|
|
Alpha-1 Antitrypsin Test (AAT) |
100-190 mg/dL |
|
|
|
|
|
|
AFP Tumor Marker |
<6.0 ng/mL |
|
|
Alzheimer's biomarkers |
|
|
|
AMAS Cancer Test |
|
|
|
Ambulatory Blood Pressure Monitor (AMBP) |
|
|
|
AMH Fertility Test |
Males |
Females |
|
|
<24 months= 14-466 ng/mL |
<24 months= <4.7 ng/mL |
|
|
24 months-12 years= 7.4-243 ng/mL |
24 months-12 years= <8.8 ng/mL |
|
|
>12 years= 0.7-19 ng/mL |
13-45 years= 0.9-9.5 ng/mL |
|
|
|
>45 years= <1.0 ng/mL |
|
Gentamicin Level |
Trough Gentamicin levels |
Peak Gentamicin levels |
|
|
Optimal: 0.5-2 µg/mL |
Optimal: 5-10 µg/mL |
|
|
Toxic: >2 µg/mL |
Toxic: >12 µg/mL |
|
|
|
|
|
Ammonia Test |
Adult= 10-80 mcg/dL or 6-47 μmol/L (SI units) |
|
|
|
Child= 40-80 mcg/dL |
|
|
|
Newborn= 90-150 mcg/dL |
|
|
|
Ammonia= < 50 mcg/dL paracentesis fluid |
|
|
|
Ammonia cerebrospinal fluid (CSF) level= 10-35 mg/dL (5.87-20.5 mmol/L) |
|
|
|
|
|
|
Amniotic Fluid Test |
Gender |
Value |
|
|
FEMALE |
Green-tinged amniotic fluid indicates fetal distress, yellow color indicates bilirubin in the fluid |
|
|
|
|
|
Amylase Test |
Serum test= Normal is 40-140 U/L |
|
|
|
Urine Test= Normal is 24-400 U/L |
|
|
|
|
|
|
c-ANCA Test |
Negative |
|
|
|
If positive for cancer, results are titered |
|
|
Androstenedione Test |
|
SI Units |
|
|
Conventional Units |
|
|
Men |
|
|
|
18-30 y |
50-220 ng/dL |
175-768 nmol/L |
|
31-50 y |
40-190 ng/dL |
140-663 nmol/L |
|
51-60 y |
50-220 ng/dL |
175-768 nmol/L |
|
Women |
|
|
|
Follicular |
35-250 ng/dL |
122-873 nmol/L |
|
Midcycle |
60-285 ng/dL |
209-995 nmol/L |
|
Luteal |
30-235 ng/dL |
105-820 nmol/L |
|
Postmenopausal |
20-75 ng/dL |
70-262 nmol/L |
|
Children |
|
|
|
1-12 mo |
6-78 ng/dL |
21-272 nmol/L |
|
1-4 y |
5-51 ng/dL |
17-178 nmol/L |
|
5-9 y |
6-115 ng/dL |
21-401 nmol/L |
|
10-13 y |
12-221 ng/dL |
42-771 nmol/L |
|
14-17 y |
22-225 ng/dL |
77-785 nmol/L |
|
Tanner II-III |
|
|
|
Male |
17-82 ng/dL |
59-286 nmol/L |
|
Female |
43-180 ng/dL |
150-628 nmol/L |
|
Tanner IV-V |
|
|
|
Male |
57-150 ng/dL |
199-523 nmol/L |
|
Female |
7-68 ng/dL |
24-237 nmol/L |
|
|
|
|
Apolipoprotein A-I Test |
Men: Greater than 120 mg/dL (1.2 g/L) |
|
|
|
Women: Greater than 140 mg/dL (1.4 g/L) |
|
|
|
|
|
|
Antimicrobial susceptibility Test |
Results are commonly reported as minimal inhibitory concentration (MIC). The interpretation usually categorizes each result as susceptible (S), intermediate (I), resistant (R), sensitive-dose dependent (SD), or no interpretation (NI) |
|
|
|
|
Anticentromere Antibody Test |
Normally, the antibodies are absent. They are detected in case of Autoimmune conditions |
|
|
|
|
|
Antidiuretic Hormone (ADH) Test |
1 - 5 pg/mL |
|
|
|
|
|
|
Anti-DNase B Test |
<5 years: < or =250 U/mL |
|
|
|
5-17 years < or =375 U/mL |
|
|
|
> or =18 years: < or =300 U/mL |
|
|
|
|
|
|
Anti-double-stranded DNA, IgG Test |
<30.0 IU/mL (negative) |
|
|
|
30.0-75.0 IU/mL (borderline) |
|
|
|
>75.0 IU/mL (positive) |
|
|
|
Negative is considered normal. |
|
|
|
|
|
|
Liver Kidney Microsomal Type 1 Antibodies Test |
< or =20.0 Units (negative) |
|
|
|
20.1-24.9 Units (equivocal) |
|
|
|
> or =25.0 Units (positive) |
|
|
|
|
|
|
Anti-Mitochondrial Antibody (AMA) Test |
Negative: <0.1 Units |
|
|
|
Borderline: 0.1-0.3 Units |
|
|
|
Weakly positive: 0.4-0.9 Units |
|
|
|
Positive: > or =1.0 Units |
Positive results for antimitochondrial antibody (AMA) of M2 specificity are highly specific for primary biliary cirrhosis (PBC) |
|
|
|
|
Antinuclear Antibodies (ANA) Test |
< or =1.0 U (negative) |
|
|
|
1.1-2.9 U (weakly positive) |
|
|
|
3.0-5.9 U (positive) |
|
|
|
> or =6.0 U (strongly positive) |
The result is positive in the case of Autoimmune disorders |
|
|
|
|
Parietal Cell Antibody, IgG Test |
Negative: < or =20.0 Units |
|
|
|
Equivocal: 20.1-24.9 Units |
|
|
|
Positive: > or =25.0 Units |
A positive result indicates the presence of IgG antibodies and suggests the possibility of pernicious anemia (PA) or a related autoimmune disease |
|
|
|
|
Antiphospholipid Antibodies (APLA) Test |
positive in APLA, IgA - persistent infection |
|
|
|
positive in APLA IgG - remote infection |
|
|
|
positive in APLA, IgM - recent infection |
|
|
|
|
|
|
Antistreptolysin O Titer Test |
<5 years: < or =70 IU/mL |
|
|
|
5-17 years: < or =640 IU/mL |
|
|
|
> or =18 years: < or =530 IU/mL |
|
|
|
|
|
|
Antithrombin III Test |
Newborn: 60%-90% |
|
|
|
Children and adults: 80%-120% |
|
|
|
Plasma concentration: 0.15-0.2 mg/mL |
|
|
|
|
|
|
Antithyroid Antibody Test |
Thyroid peroxidase antibody (TPOAb): Less than 35 IU/mL |
|
|
|
Thyroglobulin antibody (TgAb): Less than 20 IU/mL |
|
|
|
Thyroid-stimulating immunoglobulin antibody (TSI): Less than 140% of basal activity |
|
|
|
Thyroid-stimulating hormone (TSH) receptor binding inhibitor immunoglobulin (TBII)/TRAb: 1.75 IU/L or less |
|
|
|
|
|
|
Heparin Anti-Xa Test |
Adult Therapeutic Range |
|
|
|
UFH therapeutic range: 0.30-0.70 IU/mL |
|
|
|
(6 hours following initiation or dose adjustment) |
|
|
|
LMWH therapeutic range: 0.50-1.00 IU/mL for twice-daily dosing* |
|
|
|
LMWH therapeutic range: 1.00-2.00 IU/mL for once-daily dosing* |
|
|
|
LMWH prophylactic range: 0.10-0.30 IU/mL |
|
|
|
(*sample obtained 4-6 hours following subcutaneous injection) |
|
|
|
|
|
|
Apolipoprotein E Genotyping |
|
|
|
Apolipoprotein A1 Test |
Males |
|
|
|
Age |
Apolipoprotein A (mg/dL) |
|
|
<24 months |
Not Established |
|
|
2-17 years |
Low: <115 |
|
|
Borderline low: 115-120 |
|
|
Acceptable: >120 |
|
|
>18 years |
> or =120 |
|
|
|
|
|
|
Females |
|
|
|
Age |
Apolipoprotein A (mg/dL) |
|
|
<24 months |
Not Established |
|
|
2-17 years |
Low: <115 |
|
|
Borderline low: 115-120 |
|
|
Acceptable: >120 |
|
|
>18 years |
> or =140 |
|
|
Low levels of apolipoprotein A1 (ApoA1) confer an increased risk of atherosclerotic cardiovascular disease |
|
|
|
|
|
|
Apolipoprotein B Test |
Age |
Apolipoprotein B (mg/dL) |
|
|
<24 months |
Not Established |
|
|
2-17 years |
Acceptable: <90 |
|
|
|
Borderline high: 90-109 |
|
|
|
High: > or =110 |
|
|
>18 years |
Desirable: <90 |
|
|
|
Above Desirable: 90-99 |
|
|
|
Borderline high: 100-119 |
|
|
|
High: 120-139 |
|
|
|
Very high: > or =140 |
|
|
Elevated ApoB confers an increased risk of coronary artery disease |
|
|
|
|
|
|
Arbovirus Testing |
IgG: <1:10 |
|
|
|
IgM: <1:10 |
|
|
|
Reference values apply to all ages. |
|
|
|
|
|
|
ASCA Test |
a positive result is seen in the case of Crohn's disease |
|
Peritoneal Fluid Analysis |
|
|
|
Audiometry |
Hearing loss is often described as follows: |
|
|
|
Normal = less than 25 dB HL |
|
|
|
Mild = 25-40 db HL |
|
|
|
Moderate = 41-65 dB HL |
|
|
|
Severe = 66-90 db HL |
|
|
|
Profound = more than 90 dB HL |
|
|
|
|
|
|
Anti-Adrenal Antibody Test |
<1 U/mL (all ages) |
|
|
|
|
|
|
BAER/BAEP |
|
|
|
Barium Swallow Test |
|
|
|
BCGR Test |
|
|
|
BCR-ABL1 Fusion Test |
|
|
|
Beta2-Microglobulin Test |
1.21-2.70 mcg/mL |
|
|
|
|
|
|
Beta-hCG Tumor Marker Test |
Children |
|
|
|
Males |
|
|
|
Birth-3 months- < or =50 IU/L* |
|
|
|
>3 months-<18 years: <1.4 IU/L |
|
|
|
Females |
|
|
|
Birth-3 months: < or =50 IU/L* |
|
|
|
>3 months-<18 years: <1.0 IU/L |
|
|
|
|
|
|
|
Adults (97.5th percentile) |
|
|
|
Males: <1.4 IU/L |
|
|
|
Females |
|
|
|
Premenopausal, nonpregnant: <1.0 IU/L |
|
|
|
Postmenopausal: <7.0 IU/L |
|
|
|
|
|
|
Bilirubin Test |
Adult= 1.2 mg/dL of total bilirubin |
|
|
|
>18= 1 mg/dL |
|
|
|
direct bilirubin Normal= 0.3 mg/dL. |
|
|
|
|
|
|
BT CT Test |
1-9 minutes |
|
|
|
|
|
|
Blink Reflex Analysis |
|
|
|
Blood Alcohol Test |
Negative: no alcohol detected |
|
|
|
Lower limit of detection = 10 mg/dL |
|
|
|
<80 mg/dL (<17.4 mmol/L) is considered is legal intoxication |
|
|
|
>300-400 mg/dL (65.1-86.8 mmol/L) potentially fatal |
|
|
|
|
|
|
Blood Culture |
The reference range for blood culture is no growth |
|
|
|
|
|
Complete Blood Count (CBC) Test |
RED BLOOD CELL COUNT (RBC) |
|
|
|
Male Adults: 4.35-5.65 x 10(12)/L |
Female Adults: 3.92-5.13 x 10(12)/L |
|
|
HEMOGLOBIN |
|
|
|
Male Adults= 13.2-16.6 g/dL |
Female Adults= 11.6-15.0 g/dL |
|
|
HEMATOCRIT |
|
|
|
Male Adults= 38.3-48.6% |
Female Adults= 35.5-44.9% |
|
|
MEAN CORPUSCULAR VOLUME (MCV) |
|
|
Male Adults= 78.2-97.9 fL |
Female Adults= 78.2-97.9 3 fL |
|
|
RED CELL DISTRIBUTION WIDTH (RDW) |
|
|
Male Adults= 11.8-14.5% |
Female Adults= 12.2-16.1% |
|
|
WHITE BLOOD CELL COUNT (WBC) |
|
|
|
Male Adults= 3.4-9.6 x 10(9)/L |
Female Adults= 3.4-9.6 x 10(9)/L |
|
|
PLATELETS |
|
|
|
Male Adults= 135-317 x 10(9)/L |
Female Adults= 157-371 x 10(9)/L |
|
|
NEUTROPHILS |
|
|
|
Male Adults= 1.56-6.45 x 10(9)/L |
Female Adults= 1.56-6.45 x 10(9)/L |
|
|
LYMPHOCYTES |
|
|
|
Male Adults= 0.95-3.07 x 10(9)/L |
Female Adults= 0.95-3.07 x 10(9)/L |
|
|
MONOCYTES |
|
|
|
Male Adults= 0.26-0.81 x 10(9)/L |
Female Adults= 0.26-0.81 x 10(9)/L |
|
|
EOSINOPHILS |
|
|
|
Male Adults= 0.03-0.48 x 10(9)/L |
Female Adults= 0.03-0.48 x 10(9)/L |
|
|
BASOPHILS |
|
|
|
Male Adults= 0.01-0.08 x 10(9)/L |
Female Adults= 0.01-0.08 x 10(9)/L |
|
|
|
|
|
Blood Gas Analysis |
|
|
|
Blood Smear |
|
|
|
Blood Typing |
|
|
|
Blood Urea Nitrogen (BUN) TEST |
7 to 20 mg/dL (2.5 to 7.1 mmol/L) is considered normal. |
|
|
|
|
|
BMP (Basic Metabolic Panel) Test |
BUN= 7 to 20 mg/dL (2.50 to 7.14 mmol/L) |
|
|
|
CO2 (carbon dioxide)= 20 to 29 mmol/L |
|
|
|
Creatinine= 0.8 to 1.2 mg/dL (70.72 to 106.08 micromol/L) |
|
|
|
Glucose: 64 to 100 mg/dL (3.55 to 5.55 mmol/L) |
|
|
|
Serum chloride: 101 to 111 mmol/L |
|
|
|
Serum potassium: 3.7 to 5.2 mEq/L (3.7 to 5.2 mmol/L) |
|
|
|
Serum sodium: 136 to 144 mEq/L (136 to 144 mmol/L) |
|
|
|
|
|
|
BNP (Brain Natriuretic Peptide) Test |
A result greater than 100 pg/mL is abnormal. The higher the number, the more likely heart failure is present and the more severe it is |
Body Fluid Analysis |
|
|
|
Bone Marrow Aspiration and Biopsy |
|
|
|
Bone Density Test (DEXA/DXA) |
|
|
|
Biochemical Markers of Bone Remodeling |
|
|
|
BRCA1/BRCA2 Full Gene Analysis |
|
|
|
CA19-9 TEST |
less than 37 U/mL |
|
|
|
|
|
|
Calcitonin test |
Adults |
|
|
|
Males: < or =14.3 pg/mL |
Females: < or =7.6 pg/mL |
|
|
|
|
|
Calcium Levels Test |
Age 22 yr or older= 8.9-10.1 mg/dL |
|
Calreticulin (CALR) Gene Mutation Analysis |
|
|
|
Cancer Antigen 125 (CA-125) Test |
the normal value is less than 46 U/mL. |
|
|
|
|
|
|
Cancer Antigen 15-3 (CA15-3) Test |
less than 30 U/mL |
|
|
Capsule/Wireless Endoscopy |
|
|
|
|
|
|
|
Carbamazepine Level Test |
CARBAMAZEPINE, TOTAL |
|
|
|
Therapeutic: 4.0-12.0 mcg/mL |
Critical value: > or =15.0 mcg/mL |
|
|
CARBAMAZEPINE, FREE |
|
|
|
Therapeutic: 1.0-3.0 mcg/mL |
Critical value: > or =4.0 mcg/mL |
|
|
|
|
|
Cardiac Biomarkers |
|
|
|
Cardiac Stress Test |
|
|
|
|
|
|
|
Cardiolipin Antibodies (IgA, IgG, IgM) Test |
Low positive: Fewer than 20 G phospholipids (GPL), M phospholipids (MPL), A phospholipids (APL) units |
|
Medium positive: 20 or more but fewer than 80 GPL, MPL, and APL units |
|
|
High positive: 80 or more GPL, MPL, APL units |
|
|
|
|
|
|
|
|
|
Catecholamine Urine Test |
Younger than 1 year - 0-2.5 µg/24 hours |
|
|
|
Age 1 year - 0-3.5 µg/24 hours |
|
|
|
Age 2-3 years - 0-6 µg/24 hours |
|
|
|
Age 4-9 years - 0.2-10 µg/24 hours |
|
|
|
Age 10-15 years - 0.5-20 µg/24 hours |
|
|
|
Age 16 years or older - 0-20 µg/24 hours |
|
|
|
|
|
|
CCP Antibody Test |
<20.0 U (negative) |
|
|
|
20.0-39.9 U (weak positive) |
|
|
|
40.0-59.9 U (positive) |
|
|
|
> or =60.0 U (strong positive) |
|
|
|
Reference values apply to all ages. |
|
|
|
A positive result for cyclic citrullinated peptide (CCP) antibodies indicates a high likelihood of rheumatoid arthritis (RA) |
|
|
|
|
CD4 Count Test |
normal CD4 count ranges from 500–1,200 cells/mm3 in adults and teens |
|
Carcinoembryonic Antigen (CEA) Test |
Nonsmokers: < or =3.0 ng/mL |
|
|
|
Some smokers may have elevated CEA, usually <5.0 ng/mL. |
|
|
Cell-Free Fetal DNA Test |
|
|
|
Cerebrospinal Fluid (CSF) Analysis |
|
|
|
Ceruloplasmin Test |
Males: |
|
|
|
0-8 weeks: 7.4-23.7 mg/dL |
|
|
|
9 weeks-5 months: 13.5-32.9 mg/dL |
|
|
|
6-11 months: 13.7-38.9 mg/dL |
|
|
|
12 months-7 years: 21.7-43.3 mg/dL |
|
|
|
8-13 years: 20.5-40.2 mg/dL |
|
|
|
14-17 years: 17.0-34.8 mg/dL |
|
|
|
> or =18 years: 19.0-31.0 mg/dL |
|
|
|
|
|
|
|
Females: |
|
|
|
0-8 weeks: 7.4-23.7 mg/dL |
|
|
|
9 weeks-5 months: 13.5-32.9 mg/dL |
|
|
|
6-11 months: 13.7-38.9 mg/dL |
|
|
|
12 months-7 years: 21.7-43.3 mg/dL |
|
|
|
8-13 years: 20.5-40.2 mg/dL |
|
|
|
14-17 years: 20.8-43.2 mg/dL |
|
|
|
> or = 18 years: 20.0-51.0 mg/dL |
|
|
Blood Chemistry Test |
|
|
|
Chlamydia Test |
A positive test indicates an active chlamydia infection |
|
|
|
|
|
Chloride Test |
96 and 106 milliequivalents of chloride per liter of blood (mEq/L). |
|
|
|
|
|
Cholesterol (Lipid Profile) Test |
Total cholesterol |
Below 200 mg/dL |
|
|
LDL cholesterol |
Below 70 mg/dL |
|
|
HDL cholesterol |
60 mg/dL and above |
|
|
Triglycerides |
Below 150 mg/dL |
|
|
|
|
|
Cholinesterase Tests |
9572 - 15031IU/L |
|
|
|
|
|
|
Chromogranin A (CgA) Test |
<93 ng/mL |
|
|
|
|
|
|
Clostridium difficile Culture |
A positive result indicates the presence of viable Clostridium difficile in the stool. |
|
|
|
|
|
Cytomegalovirus (CMV) Antibody (IgG and IgM) |
CMV IgM: Negative |
Positive IgM antibodies indicate recent infection |
|
CMV IgG: Negative |
Positive IgG antibodies indicate remote infection |
|
|
|
|
Prothrombin Time and International Normalized Ratio (INR) |
prothrombin time = 9.5-13.5 seconds |
|
|
international normalized ratio (INR) = less than 1.3 |
|
|
|
|
|
Cold Agglutinins Test |
<1:64 titer |
|
|
Colonoscopy |
A colonoscopy is considered negative if the doctor doesn't find any abnormalities in the colon. |
Color Doppler Ultrasound |
|
|
|
Complement Test |
> or =16 years: 30-75 U/mL |
|
|
|
|
|
|
Comprehensive Metabolic Panel (CMP) Test |
SODIUM |
> or =1 year: 135-145 mmol/L |
|
|
POTASSIUM |
> or =1 year: 3.6-5.2 mmol/L |
|
|
CHLORIDE |
> or =18 years: 98-107 mmol/L |
|
|
BICARBONATE |
|
|
|
Males: |
> or =18 years: 22-29 mmol/L |
|
|
Females: |
> or =10 years: 22-29 mmol/L |
|
|
|
|
|
|
ANION GAP |
> or =7 years: 7-15 |
|
|
BLOOD UREA NITROGEN (BUN) |
|
|
|
Males: |
> or =18 years: 8-24 mg/Dl |
|
|
Females: |
> or =18 years: 6-21 mg/dL |
|
|
|
|
|
|
CREATININE |
|
|
|
Males: |
> or =15 years: 0.74-1.35 mg/dL |
|
|
Females: |
> or =16 years: 0.59-1.04 mg/dL |
|
|
|
|
|
|
ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) |
>60 mL/min/BSA |
|
|
CALCIUM |
|
|
|
<1 year: 8.7-11.0 mg/dL |
|
|
|
1-17 years: 9.3-10.6 mg/dL |
|
|
|
18-59 years: 8.6-10.0 mg/dL |
|
|
|
60-90 years: 8.8-10.2 mg/dL |
|
|
|
>90 years: 8.2-9.6 mg/dL |
|
|
|
|
|
|
|
GLUCOSE |
> or =1 year: 70-140 mg/dL |
|
|
TOTAL PROTEIN |
> or =1 year: 6.3-7.9 g/dL |
|
|
ALBUMIN |
> or =12 months: 3.5-5.0 g/dL |
|
|
ASPARTATE AMINOTRANSFERASE (AST) |
|
|
Males: |
> or =14 years: 8-48 U/L |
|
|
Females: |
> or =14 years: 8-43 U/L |
|
|
|
|
|
|
ALKALINE PHOSPHATASE (ALP) |
|
|
|
Males: |
> or =19 years: 45-115 U/L |
|
|
Females: |
16 years: 61-264 U/L |
|
|
|
17-23 years: 52-144 U/L |
|
|
|
24-45 years: 37-98 U/L |
|
|
|
46-50 years: 39-100 U/L |
|
|
|
51-55 years: 41-108 U/L |
|
|
|
56-60 years: 46-118 U/L |
|
|
|
61-65 years: 50-130 U/L |
|
|
|
> or =66 years: 55-142 U/L |
|
|
|
|
|
|
ALANINE AMINOTRANSFERASE (ALT) |
|
|
Males: |
> or =1 year: 7-55 U/L |
|
|
Females: |
> or =1 year: 7-45 U/L |
|
|
|
|
|
|
TOTAL BILIRUBIN |
>18 years: < or =1.2 mg/dL |
|
|
|
|
|
|
|
|
|
Coombs (Direct Antiglobulin) Test |
Results are considered normal if there’s no clumping of red blood cells |
|
|
|
|
Cortisol Level Test |
Morning - 7-28 μg/dL |
|
|
|
Afternoon - 2-18 μg/dL |
|
|
|
|
|
|
C-peptide Test |
0.8-3.1 ng/mL |
|
|
|
|
|
|
Creatine Kinase (CK)-MB Test |
Male= 171 U/L |
|
|
|
Female= 145 U/L |
|
|
|
|
|
|
High-sensitivity C-reactive Protein Test |
CRP: 0-10mg/L |
|
|
|
High-sensitivity CRP (hs-CRP): < 3 mg/L |
|
|
|
|
|
|
Creatine Kinase (CK) Test |
Males |
>3 months: 39-308 U/L |
|
|
Females |
>3 months: 26-192 U/L |
|
|
|
|
|
Creatinine Clearance Test |
Male serum age 16 years or older - 0.8-1.3 mg/dL |
|
|
Female serum age 16 years or older - 0.6-1.1 mg/dL |
|
|
24-hour urine creatinine level is 500-2000 mg/day |
|
|
|
|
|
Creatinine Test |
Serum creatinine |
|
|
|
Adult males: 0.5–1.2 mg/dL* |
|
|
|
Adult females: 0.4 – 1.1 mg/dL* |
|
|
|
Children (up to 12 years of age): 0.0–0.7 mg/dL |
|
|
|
|
|
|
Urine creatinine |
|
|
|
Adult males: 20-25 mg/kg/day (roughly 1575 mg/day for a 70-kg male) |
|
|
|
Adult females: 15-20 mg/kg/day (roughly 1050 mg/day for a 60-kg female) |
|
|
|
|
|
|
C Reactive Protein (CRP) Test |
< or =8.0 mg/L |
|
|
|
|
|
|
Cryoproteins Test |
CRYOGLOBULIN= Negative |
|
|
|
CRYOFIBRINOGEN = Negative |
|
|
CT scan |
|
|
|
Cyclosporine Test |
100-400 ng/mL (Trough) |
|
|
|
|
|
|
Cystatin C Test |
Males: |
|
|
|
0 days-22 years: no reference values established |
|
|
|
23-29 years: 0.60-1.03 mg/L |
|
|
|
30-39 years: 0.64-1.12 mg/L |
|
|
|
40-49 years: 0.68-1.22 mg/L |
|
|
|
50-59 years: 0.72-1.32 mg/L |
|
|
|
60-69 years: 0.77-1.42 mg/L |
|
|
|
70-79 years: 0.82-1.52 mg/L |
|
|
|
>79 years: no reference values established |
|
|
|
|
|
|
|
Females: |
|
|
|
0 days-22 years: no reference values established |
|
|
|
23-29 years: 0.57-0.90 mg/L |
|
|
|
30-39 years: 0.59-0.98 mg/L |
|
|
|
40-49 years: 0.62-1.07 mg/L |
|
|
|
50-59 years: 0.64-1.17 mg/L |
|
|
|
60-69 years: 0.66-1.26 mg/L |
|
|
|
70-80 years: 0.68-1.36 mg/L |
|
|
|
81-86 years: 0.70-1.45 mg/L |
|
|
|
>86 years: no reference values established |
|
|
|
|
|
|
|
eGFR >60 mL/min/BSA |
|
|
|
eGFR will not be calculated for patients under 18 years |
|
|
|
|
|
|
Cystic Fibrosis Gene Mutation Testing |
|
|
|
Cytogenetics Test |
|
|
|
Des-Gamma-Carboxy Prothrombin (DCP) Test |
<7.5 ng/mL |
|
|
|
|
|
|
D-dimer Test |
< or =500 ng/mL Fibrinogen Equivalent Units (FEU) |
|
|
|
|
|
Dengue Antibodies (IgG, IgM) Test |
IgG: negative |
|
|
|
IgM: negative |
|
|
Dental Cone Beam CT (CBCT) |
|
|
|
Dental Orthopantomogram (OPG) |
|
|
|
|
|
|
|
DHEA-sulfate Test |
Age |
Male |
Female |
|
18-29 years |
89-457 mcg/dL |
44-332 mcg/dL |
|
30-39 years |
65-334 mcg/dL |
31-228 mcg/dL |
|
40-49 years |
48-244 mcg/dL |
18-244 mcg/dL |
|
50-59 years |
35-179 mcg/dL |
< 15-200 mcg/dL |
|
≥ 60 years |
25-131 mcg/dL |
< 15-157 mcg/dL |
|
|
|
|
Digoxin Test |
0.8-2 ng/mL (1.2-2 nmol/L) |
|
|
|
Half-life: 36 hours |
|
|
|
Toxic level: more than 2 ng/mL |
|
|
|
|
|
|
|
|
|
|
Urine Drug Test |
results in terms of positive or negative |
|
D-Xylose Absorption Test |
|
|
|
E. coli Test |
|
|
|
Echocardiogram (a cardiac ultrasound) |
|
|
|
Echocardiography Test |
|
|
|
EGFR Mutation Test |
|
|
|
eGFR Test |
> 90ml/min/1.73 metre square |
|
|
Electrocardiogram (ECG) Test |
|
|
|
Electroencephalogram (EEG) Test |
|
|
|
|
|
|
|
Electrolyte Test |
Ammonia: 15-50 µmol/L |
|
|
|
Ceruloplasmin: 15-60 mg/dL |
|
|
|
Chloride: 95-105 mmol/L |
|
|
|
Copper: 70-150 µg/dL |
|
|
|
Creatinine: 0.8-1.3 mg/dL |
|
|
|
Blood urea nitrogen: 8-21 mg/dL |
|
|
|
Ferritin: 12-300 ng/mL (men), 12-150 ng/mL (women) |
|
|
|
Glucose: 65-110 mg/dL |
|
|
|
Inorganic phosphorous: 1-1.5 mmol/L |
|
|
|
Ionized calcium: 1.03-1.23 mmol/L |
|
|
|
Magnesium: 1.5-2 mEq/L |
|
|
|
Phosphate: 0.8-1.5 mmol/L |
|
|
|
Potassium: 3.5-5 mmol/L |
|
|
|
Pyruvate: 300-900 µg/dL |
|
|
|
Sodium: 135-145 mmol/L |
|
|
|
Total calcium: 2-2.6 mmol/L (8.5-10.2 mg/dL) |
|
|
|
Total iron-binding capacity: 45-85 µmol/L |
|
|
|
Total serum iron: 65-180 µg/dL (men), 30-170 µg/dL (women) |
|
|
|
Transferrin: 200-350 mg/dL |
|
|
|
Urea: 1.2-3 mmol/L |
|
|
|
Uric acid: 0.18-0.48 mmol/L |
|
|
|
Zinc: 70-100 µmol/L |
|
|
|
https://emedicine.medscape.com/article/2172316-overview |
|
|
|
|
|
Electromyography (EMG) Test |
|
|
|
|
|
|
|
Extractable Nuclear Antigen (ENA) Antibodies |
SS-A/Ro ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
SS-B/La ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
Sm ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
RNP ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
Scl 70 ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
Jo 1 ANTIBODIES, IgG |
<1.0 U (negative) |
> or =1.0 U (positive) |
|
|
|
|
|
Reference values apply to all ages |
|
|
Endoscopic Retrograde Cholangiopancreatography (ERCP) Test |
|
|
|
Endoscopy |
|
|
|
Epstein-Barr Virus Antibodies Test |
Epstein-Barr Virus (EBV) VIRAL CAPSID ANTIGEN (VCA) IgM ANTIBODY |
Negative |
|
|
Epstein-Barr Virus (EBV) VIRAL CAPSID ANTIGEN (VCA) IgG ANTIBODY |
Negative |
|
|
EPSTEIN-BARR NUCLEAR ANTIGEN (EBNA) ANTIBODIES |
Negative |
|
Erythropoietin Test |
Adults: 4.1-19.5 mU/mL |
|
|
|
Infants aged 3 weeks to 2 months: 5-13 mU/mL |
|
|
Children aged 3 months to 16 years: 9-28 mU/mL |
|
|
|
|
|
Erythrocyte Sedimentation Rate (ESR) Test |
0-22 mm/hr for men |
|
|
|
0-29 mm/hr for women |
|
|
|
|
|
|
Estradiol Test |
ADULTS Males: 10-40 pg/Ml |
|
|
|
ADULTS Females |
Premenopausal: 15-350 pg/mL** |
|
|
|
Postmenopausal: <10 pg/mL |
|
|
**E2 levels vary widely through the menstrual cycle. |
|
|
|
|
|
F wave Test |
|
|
|
F-actin Antibody Test |
Negative: <20.0 U |
|
|
|
Weak Positive: 20.0-30.0 U |
|
|
|
Positive: >30.0 U |
|
|
|
|
|
|
Factor V Leiden Mutation Test |
70-150% of normal |
|
|
Calprotectin Test |
< or =50.0 mcg/g (Normal) |
|
|
|
50.1-120.0 mcg/g (Borderline) |
|
|
|
> or =120.1 mcg/g (Abnormal) |
|
|
|
Reference values apply to all ages. |
|
|
|
|
|
|
|
|
|
|
Stool Chymotrypsin Test |
|
|
|
Fecal Elastase-1 Test |
|
|
|
Fecal Fat Test |
2 to 7 grams over 24 hours. |
|
|
Fecal immunochemical Test (FIT) |
|
|
|
Fecal Occult Blood Test |
A fecal occult blood test is considered negative if no blood is detected in your stool samples |
|
|
|
|
Ferritin Test |
Males: 23-336 ng/mL |
|
|
|
Females: 11-306 ng/mL |
|
|
Fetal Fibronectin Test |
|
|
|
Fibrinogen Test |
Fibrinogen antigen: 149-353 mg/dL |
|
|
Fibrinogen: 150-400 mg/dL |
|
|
|
Fibrinogen antigen/functional ratio: 0.59-1.23 |
|
|
|
|
|
First Trimester Screen Test |
|
|
|
Fistulogram Test |
|
|
|
Flow Cytometry Test |
|
|
|
Fluorescence In Situ Hybridization (FISH) Test |
|
|
|
Fluoroscopy |
|
|
|
Folic Acid (Folate) Test |
Adults: 2-20 ng/mL, or 4.5-45.3 nmol/L |
|
|
|
Children: 5-21 ng/mL, or 11.3-47.6 nmol/L |
|
|
|
Infants: 14-51 ng/mL, or 31.7-115.5 nmol/L |
|
|
|
|
|
|
Follicle-stimulating Hormone (FSH) Test |
Females |
|
|
|
Age 0-7 years: <6.7 mIU/mL |
|
|
|
Age 8 years to adult: |
|
|
|
Follicular phase: 3.1-7.9 mIU/mL |
|
|
|
Ovulation peak: 2.3-18.5 mIU/mL |
|
|
|
Luteal phase: 1.4-5.5 mIU/mL |
|
|
|
Postmenopausal: 30.6-106.3 mIU/mL |
|
|
|
|
|
|
|
Males |
|
|
|
Age 0-7 years: <6.7 mIU/mL |
|
|
|
Age 8 years-adult:1.3-19.3 mIU/mL |
|
|
Fructosamine Test |
200-285 µmol/L, when the serum albumin concentration level is 5 g/dL |
|
|
|
|
|
Fungal Culture |
In normal circumstances, fungal culture results are negative |
|
|
|
|
|
G6PD Test |
> or =12 months: 8.8-13.4 U/g Hb |
|
|
Gastrin Hormone Test |
0-100 pg/mL. |
|
|
Gene Expression Profiling |
|
|
|
Genomic Testing for Cancer Treatment |
|
|
|
GGT Test |
0-30 IU/L |
|
|
|
|
|
|
Gastrointestinal Pathogens Panel Test |
Negative (for all targets) |
|
|
|
|
|
|
Oral Glucose Tolerance Test (OGTT) |
Fasting plasma glucose: 70-99 mg/dL |
|
|
|
Postprandial plasma glucose at 2 hours: Less than 140 mg/dL |
|
|
|
Random plasma glucose: Less than 140 mg/dL |
|
|
|
|
|
|
Gonorrhea Test |
|
|
|
Graded Exercise Test (GXT) |
|
|
|
Gram Stain Test |
A normal value is defined as no pathologic organism seen in the smear |
|
|
|
|
Group B Strep Test |
If you test positive for group B strep, means the potential for newborn infection exists |
|
|
|
|
|
Growth Hormone Test |
Adult Males: 0.01-0.97 ng/mL |
|
|
|
Adult Females: 0.01-3.61 ng/mL |
|
|
|
|
|
|
H pylori Test |
Positive: H pylori antigen detected |
|
|
|
|
|
Haptoglobin Test |
Male/Female adults= 30-200 mg/dL |
|
|
|
|
|
hCG Pregnancy Test |
Pediatric males |
|
|
|
Birth-3 months - 50 IU/L or less |
3 months-18 years - 0.8 IU/L or less |
|
Pediatric females |
|
|
|
Birth-3 months - 50.0 IU/L* or less |
3 months-18 years - 2.3 IU/L or less |
|
|
|
|
|
Adult Males - 0.8 IU/L or less |
|
|
|
Adult Females - Premenopausal, nonpregnant: 2.3 IU/L or less. Postmenopausal: 7.3 IU/L or less. |
|
|
|
|
|
|
|
|
HE4 Test |
Females: < or =140 pmol/L |
|
|
|
Males: Not applicable |
|
|
Heart Disease Risk Assessment |
|
|
|
Heavy Metals Test |
ARSENIC |
0-12 ng/mL |
|
|
LEAD |
0.0-4.9 mcg/dL |
|
|
CADMIUM |
0.0-4.9 ng/mL |
|
|
MERCURY |
0-9 ng/mL |
|
|
Reference values apply to all ages. |
|
|
|
|
|
|
Hematocrit Test |
For men, 38.8 to 50 percent |
|
|
|
For women, 34.9 to 44.5 percent |
|
|
|
|
|
|
Hemoglobin A1c Test |
below 5.7 percent. |
|
|
Hemoglobin Electrophoresis Test |
HbA1: 95%-98% |
|
|
|
HbA2: 1.5%-3.5% |
|
|
|
HbF: < 2% (age-dependent) |
|
|
|
HbC: Absent |
|
|
|
HbS: Absent |
|
|
|
|
|
|
Hemoglobin Test |
For men, 13.5 to 17.5 grams per deciliter |
|
|
|
For women, 12.0 to 15.5 grams per deciliter |
|
|
|
|
|
|
Heparin-PF4 IgG Antibody Test |
HIT ELISA <0.400 |
|
|
|
|
|
|
Hepatitis A IgM Antibody Test |
Negative indicates the absence of acute or recent hepatitis A |
|
|
|
|
|
Hepatitis B Test |
HEPATITIS B SURFACE ANTIBODY |
|
|
|
Unvaccinated: negative |
Vaccinated: Positive |
|
|
HEPATITIS B SURFACE ANTIBODY, QUANTITATIVE |
|
|
Unvaccinated: <5.0 mIU/mL |
Vaccinated: > or =12.0 mIU/mL |
|
|
|
|
|
Hepatitis C Viral Load Test |
The undetected result indicates that the HCV is absent in the patient's serum specimen |
|
|
|
|
|
Acute Viral Hepatitis Serology Panel Test |
|
|
|
HER2(ERBB2) Amplification |
|
|
|
Herpes Simplex Virus, Type 1 and Type 2 Test |
|
|
|
HIDA Scan |
|
|
|
Histamine Test |
Histamine, 24-hour Urine: 0.006 – 0.131 mg/24 h |
|
|
|
|
|
Histone Antibody Test |
<1.0 Units (negative) |
|
|
|
1.0-1.5 Units (borderline) |
|
|
|
>1.5 Units (positive) |
|
|
|
Reference values apply to all ages |
|
|
HIV Genotypic Resistance Test |
|
|
|
HIV Viral Load Test |
|
|
|
HLA B22 Test |
|
|
|
HLA-B27 Test |
|
|
|
Holter Monitor Test |
|
|
|
Homocysteine Test |
Age 0-30 years: 4.6-8.1 µmol/L |
|
|
|
Age 30-59 years: 6.3-11.2 µmol/L (males); 4-5-7.9 µmol/L (females) |
|
|
Age >59 years: 5.8-11.9 µmol/L |
|
|
|
|
|
|
Estrogen and Progesterone Receptor Status Test |
Negative: <1% reactive cells |
|
|
|
Positive: >1% reactive cells |
|
|
|
|
|
|
Genital HPV Test |
A positive test result means that you have a type of high-risk HPV that's linked to cervical cancer. |
H-reflex Test |
|
|
|
HTLV Test |
Negative |
|
|
|
|
|
|
17-Hydroxyprogesterone Test |
Adult Males: <220 ng/dL |
|
|
|
Adult Females |
|
|
|
Follicular: <80 ng/dL |
|
|
|
Luteal: <285 ng/dL |
|
|
|
Postmenopausal: <51 ng/dL |
|
|
|
|
|
|
Insulin-like Growth Factor (IGF)- 1 |
too many results |
|
|
Immunoglobulins IgG,lgA,lgM Test |
IgG |
> or =18 years: 767-1,590 mg/dL |
|
|
IgA |
> or =18 years: 61-356 mg/dL |
|
|
IgM |
> or =18 years: 37-286 mg/dL |
|
|
|
|
|
Immunophenotyping Test |
|
|
|
Immunoreactive Trypsinogen (IRT) Test |
|
|
|
Implantable Loop Record Test |
|
|
|
Insulin Antibodies Test |
< or =0.02 nmol/L |
Reference values apply to all ages. |
|
|
|
|
|
Insulin Test |
Fasting |
< 25 mIU/L |
|
|
30 minutes after glucose administration |
30-230 mIU/L |
|
|
1 hour after glucose administration |
18-276 mIU/L |
|
|
2 hours after glucose administration |
16-166 mIU/L |
|
|
≥3 hours after glucose administration |
< 25 mIU/L |
|
|
|
|
|
Interleukin-6 (IL-6) Test |
< or =1.8 pg/mL |
|
|
IVU (Intravenous urogram) or IVP (Intravenous pyelogram) |
|
|
|
Intrinsic Factor Antibody Test |
Negative |
|
|
|
|
|
|
Iron Test |
Men= 55–160 µg/dL |
|
|
|
Women= 40–155 µg/dL |
|
|
JAK2 Mutation Test |
|
|
|
Chromosome Analysis (Karyotyping) |
|
|
|
Keppra (Levetiracetam) Test |
12.0-46.0 mcg/mL |
|
|
|
|
|
|
Ketone Test |
less than 1 mg/dL |
|
|
Renal (Kidney) Function Panel Test |
|
|
|
Kidney Stone Analysis |
|
|
|
KRAS Mutation Analysis |
|
|
|
Lactate Dehydrogenase (LD) Test |
> or =18 years: 122-222 U/L |
|
|
|
|
|
|
Lactate (Lactic Acid) Test |
0.5 - 1mmol/L |
|
|
Lactoferrin Test |
|
|
|
Lactose Tolerance Test |
|
|
|
LDL Subfraction Profile Test |
|
|
|
Lead Test |
LEAD |
0.0-4.9 mcg/dL |
|
|
|
|
|
Legionella Test |
Negative |
|
|
|
|
|
|
Leptin Test |
MALE |
0.3 - 13.4 ng/ml |
|
|
FEMALE |
4.7 - 23.7 ng/ml |
|
|
|
|
|
Lipase Test |
0-50 U/L |
|
|
|
|
|
|
Lipoprotein- A Test |
< or =30 mg/dL |
|
|
|
Values >30 mg/dL may suggest an increased risk of coronary heart disease. |
|
|
|
|
|
|
Lithium Test |
Therapeutic: 0.5-1.2 mmol/L (trough concentration) |
|
|
|
Critical value: >1.6 mmol/L |
|
|
|
|
|
|
Liver Function Test |
Alanine transaminase (ALT)= 7 to 55 units per liter (U/L) |
|
|
|
Aspartate transaminase (AST)= 8 to 48 U/L |
|
|
|
Alkaline phosphatase (ALP)= 45 to 115 U/L |
|
|
|
Albumin. 3.5 to 5.0 grams per deciliter (g/dL) |
|
|
|
Total protein. 6.3 to 7.9 g/dL |
|
|
|
Bilirubin. 0.1 to 1.2 milligrams per deciliter (mg/dL) |
|
|
|
Gamma-glutamyltransferase (GGT)= 9 to 48 U/L |
|
|
|
L-lactate dehydrogenase (LD)= 122 to 222 U/L |
|
|
|
Prothrombin time (PT)= 9.5 to 13.8 seconds |
|
|
|
|
|
|
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Test |
|
|
|
Lung Cancer Test |
|
|
|
Lupus Anticoagulant Test |
PROTHROMBIN TIME (PT) |
10.3-12.8 seconds |
|
|
|
|
|
Luteinizing Hormone (LH) Test |
Males |
>18 years: 1.3-9.6 IU/L |
|
|
Females |
|
|
|
Premenopausal: |
|
|
|
Follicular: 1.9-14.6 IU/L |
|
|
|
Midcycle: 12.2-118.0 IU/L |
|
|
|
Luteal: 0.7-12.9 IU/L |
|
|
|
Postmenopausal: 5.3-65.4 IU/L |
|
|
|
|
|
|
Lyme Disease Test |
Negative |
|
|
|
|
|
|
Magnesium RBC Test |
3.5 - 7.1 mg/dL |
|
|
Magnetic Resonance Imaging (MRI) Test |
|
|
|
Mammography |
|
|
|
Maternal Serum Screen Test |
|
|
|
Measles (Rubeola) Antibodies, IgG and IgM Test |
|
|
|
Mumps Antibody, IgM, and IgG |
|
|
|
|
|
|
|
Mercury Test |
Normal: 0-9 ng/mL |
|
|
Soluble Mesothelin-Related Peptide Test |
|
|
|
|
|
|
|
Urine Metanephrines Test |
MALE |
44 - 261 mcg/24 hrs |
|
|
FEMALE |
30 - 180 mcg/24 hrs |
|
|
|
|
|
Methotrexate Test |
Nontoxic drug concentration after 72 hours: <0.1 mcmol/L |
|
|
|
|
|
Methylmalonic Acid Test |
0-0.4 µmol/L (0-4.7 µg/dL). |
|
|
|
|
|
|
Microalbumin Test |
Less than 30 mg per 24 hours is normal |
|
|
Micturating/Voiding Cystourethrogram Test |
|
|
|
Infectious Mononucleosis Rapid Test |
Negative |
|
|
MRSA Screening Test |
|
|
|
MTHFR A1298C Mutation Analysis Test |
Negative |
|
|
|
|
|
|
MTHFR C677T Mutation Analysis Test |
Negative |
|
|
MUGA Scan Test |
|
|
|
Mycophenolic Acid Test |
1.0-3.5 mcg/mL |
|
|
Mycoplasma pneumonia Antibodies |
|
|
|
Myoglobin Test |
< or =90 mcg/L |
|
|
Nerve Conduction Velocity (NCV) Test |
|
|
|
Nicotine / Cotinine Test |
NICOTINE |
<3.0 ng/mL |
|
|
COTININE |
<3.0 ng/mL |
|
Non-HDL Cholesterol Test |
|
|
|
|
|
|
|
Opioid Testing |
|
|
|
Osmolality Test |
serum osmolality = 275–295 mosm/kg (mmol/kg) |
|
|
|
|
|
Ova and Parasite Test |
negative (no parasites seen). |
|
|
Overdose Drug Test |
|
|
|
p24 Antigen Test |
|
|
|
Pap Smear Test |
|
|
|
Parathyroid Hormone (PTH) Test |
10-65 pg/mL or 10-65 ng/L |
|
|
Parvovirus B19 Test |
|
|
|
Pericardial Fluid Analysis |
|
|
|
|
|
|
|
Pertussis Test |
negative |
|
|
Pharmacogenomic (PGX) Tests |
|
|
|
Phenobarbital Test |
Therapeutic: 10.0-40.0 mcg/mL |
|
|
|
Critical value: > or =60.0 mcg/mL |
|
|
|
|
|
|
Phenytoin Test |
Children and adults: 10-20 µg/mL |
|
|
|
Neonates: 8-15 µg/mL |
|
|
|
|
|
|
Phosphorus Test |
Adults Males/Females- 2.5-4.5 mg/Dl |
|
Platelet Count |
150,000 to 450,000/mcL |
|
|
Platelet Function Tests |
|
|
|
Clopidogrel (CYP2C19 Genotyping) Test |
|
|
|
Pleural Fluid Analysis |
|
|
|
PML-RARA Test |
|
|
|
Porphobilinogen Test |
< or =1.3 mcmol/L |
|
|
PET CT Scan |
|
|
|
Potassium Test |
serum/plasma potassium levels |
Adults: 3.5-5.1 mEq/L or mmol/L |
|
|
urinary potassium levels |
25-125 mEq/L/day |
|
|
|
|
|
Prealbumin (Transthyretin) Test |
19-38 mg/dL |
|
|
|
|
|
|
Pregnenolone Test |
33-248 ng/dL |
|
|
|
|
|
|
Procalcitonin Test |
Adults and children > or =72 hours: < or =0.15 ng/mL |
|
Proctoscopy |
|
|
|
Progesterone Test |
Adult Males |
<0.20 ng/mL |
|
|
Adult Females |
|
|
|
Follicular phase: < or =0.89 ng/mL |
|
|
|
Ovulation: < or =12 ng/mL |
|
|
|
Luteal phase: 1.8-24 ng/mL |
|
|
|
Post-menopausal: < or =0.20 ng/mL |
|
|
|
|
|
|
Prolactin Test |
Females: |
|
|
|
Nongravid/nonlactating: 2-29 ng/mL |
|
|
|
Gravid: 10-209 ng/mL (third trimester) |
|
|
|
Males = 2-18 ng/mL |
|
|
MRI Spectroscopy |
|
|
|
Prostate Specific Antigen (PSA) Test |
|
|
|
|
|
|
|
Protein C and S Test |
Protein C level in a healthy adult= 65-135 IU/dL |
|
|
|
|
|
Protein Electrophoresis Test |
Albumin: 3.3-5.7 g/dL |
|
|
|
alpha-1: 0.1-0.4 g/dL |
|
|
|
alpha-2: 0.3-0.9 g/dL |
|
|
|
beta-2: 0.7-1.5 g/dL |
|
|
|
gamma: 0.5-1.4 g/dL |
|
|
|
|
|
|
Urine Protein Test |
|
|
|
Prothrombin 20210 Mutation Test |
Negative |
|
|
|
|
|
|
Prothrombin Time and INR Test |
prothrombin time= 9.5-13.5 seconds |
|
|
International Normalized Ratio (INR)= less than 1.3 |
|
|
|
|
|
PSEN1 Genetic Mutation Analysis |
|
|
|
Partial Thromboplastin Time (PTT, aPTT) Test |
aPTT = 30-40 seconds |
|
|
|
PTT = 60-70 seconds |
|
|
Pulmonary Function Tests (PFT) |
|
|
|
Radioactive iodine uptake test |
|
|
|
Influenza Tests |
|
|
|
RBC Antibody Screen Test |
|
|
|
Red Blood Cell Count (RBC) Test |
|
|
|
Red blood cell indices Test |
|
|
|
Repetitive Nerve Stimulation Test (RNST) |
|
|
|
Reticulocyte count |
0.5 percent to 1.5 percent. |
|
|
|
|
|
|
Rheumatoid Factor (RF) Test |
less than 15 IU/mL or less than 1:16 |
|
|
Respiratory Syncytial Virus (RSV) Test |
|
|
|
Rubella Antibody Test |
|
|
|
Salicylates Test |
Therapeutic: <30.0 mg/dL |
|
|
|
Critical value: > or =50.0 mg/dL |
|
|
Semen Analysis |
|
|
|
|
|
|
|
Serotonin Test |
101 - 283ng/ml |
|
|
|
|
|
|
Albumin Serum Test |
> or =12 months: 3.5-5.0 g/dL |
|
|
Serum-free light-chain Test |
|
|
|
SGOT (AST) Test |
|
|
|
SGPT (ALT) Test |
|
|
|
SHBG Test |
Males: 10-57 nmol/L |
|
|
|
Females (non-pregnant): 18-144 nmol/L |
|
|
|
|
|
|
Sialography Test |
|
|
|
Sickle Cell Test |
|
|
|
Sigmoidoscopy Test |
|
|
|
|
|
|
|
Sirolimus Test |
4-20 ng/mL (Trough) |
|
|
Smooth Muscle Antibody (SMA) Test |
|
|
|
Sodium Test |
135 - 145mmol/L |
|
|
|
|
|
|
Soluble Transferrin Receptor Test |
Men: 2.2-5 mg/L |
|
|
|
Women: 1.9-4.4 mg/L |
|
|
|
|
|
|
Somatosensory Evoked Potential (SSEP) Test |
|
|
|
Sputum Culture Test |
|
|
|
STD Testing |
|
|
|
Stool Culture Test |
|
|
|
Sweat Chloride Test |
|
|
|
Synovial Fluid Analysis |
|
|
|
Syphilis Detection Tests |
|
|
|
T-Cell Receptor Gene Rearrangement Test |
|
|
|
|
|
|
|
Tacrolimus Test |
5-15ng/ml |
|
|
|
|
|
|
Testosterone Test |
MALE |
270 - 1070 ng/dl |
|
|
FEMALE |
8 - 60 ng/dl |
|
|
|
|
|
Theophylline and Caffeine Test |
Adults: 5-15 µg/mL |
|
|
Therapeutic Drug Monitoring Test |
|
|
|
Throat Culture Test |
|
|
|
|
|
|
|
Thrombin Time Test |
15-19 seconds |
|
|
|
|
|
|
Thyroglobulin Test |
|
|
|
|
THYROGLOBULIN, TUMOR MARKER |
|
|
|
Athyrotic: <0.1 ng/mL |
Intact thyroid < or =33 ng/mL |
|
|
|
|
|
Thyroid Function Tests |
TSH |
0.4 and 4.0 mIU/L of blood. |
|
|
T3 |
100–200 nanograms of hormone per deciliter of blood (ng/dL) |
|
|
|
|
Thyroid-stimulating Hormone (TSH) Test |
TSH |
0.4 and 4.0 mIU/L of blood. |
|
|
|
|
|
TORCH Test |
|
|
|
Total CO2 (Bicarbonate) Test |
|
23 to 29 mEq/L |
|
|
|
|
|
Total IgE (Immunoglobulin E) Test |
Adult -< or =214 kU/L |
|
|
|
|
|
|
Total Iron Binding Capacity (TIBC) Test |
255-450 μg/dL |
|
|
Total Protein and A/G Ratio Test |
|
|
|
Toxoplasmosis Test |
|
|
|
TPMT Test |
|
|
|
Trace Minerals Test |
|
|
|
Transesophageal Echocardiogram (TEE) Test |
|
|
|
Transvaginal Scan (TVS) Test |
|
|
|
Treadmill Stress Test (TMT) |
|
|
|
Trichomonas vaginalis test |
|
|
|
Triglycerides Test |
Less than 150 mg/Dl |
|
|
|
|
|
|
Troponin Test |
< or =0.04 ng/mL |
|
|
|
|
|
|
Total Tryptase Test |
< 11.4 ng/mL |
|
|
|
|
|
|
Tissue Transglutaminase (TTG) Antibody, IgA Test |
|
|
|
Tuberculin Skin Test |
|
|
|
Tumor Markers Test |
|
|
|
Ultrasound (Sonography) Test |
|
|
|
Urea Breath Test |
|
|
|
Uric Acid Test |
Men: 2.5-8 mg/dL |
|
|
|
Women: 1.9–7.5 mg/dL |
|
|
|
|
|
|
Urinalysis |
Color – Yellow (light/pale to dark/deep amber) |
|
|
|
Clarity/turbidity – Clear or cloudy |
|
|
|
pH – 4.5-8 |
|
|
|
Specific gravity – 1.005-1.025 |
|
|
|
Glucose - ≤130 mg/d |
|
|
|
Ketones – None |
|
|
|
Nitrites – Negative |
|
|
|
Leukocyte esterase – Negative |
|
|
|
Bilirubin – Negative |
|
|
|
Urobilirubin – Small amount (0.5-1 mg/dL) |
|
|
|
Blood - ≤3 RBCs |
|
|
|
Protein - ≤150 mg/d |
|
|
|
RBCs - ≤2 RBCs/hpf |
|
|
|
WBCs - ≤2-5 WBCs/hpf |
|
|
|
Squamous epithelial cells - ≤15-20 squamous epithelial cells/HPF |
|
|
|
Casts – 0-5 hyaline casts/lpf |
|
|
|
Crystals – Occasionally |
|
|
|
Bacteria – None |
|
|
|
Yeast - None |
|
|
|
|
|
|
Urine Culture Test |
No growth in 24-48 hours |
|
|
|
|
|
|
|
|
|
|
Urine Copper Test |
> or =18 years: < or =60 mcg/24h |
|
|
|
|
|
|
Valproic Acid Test |
VALPROIC ACID, TOTAL |
|
|
|
Therapeutic: 50 (trough)-125 (peak) mcg/mL |
|
|
|
Critical value: > or =151 mcg/mL |
|
|
|
|
|
|
|
VALPROIC ACID, FREE |
|
|
|
Therapeutic: 5-25 mcg/mL |
|
|
|
Critical value: >30 mcg/mL |
|
|
|
|
|
|
Vancomycin Test |
Trough levels is 10-20 µg/mL (15-20 µg/mL for complicated infections) |
|
Peak levels are 25-50 µg/mL. |
|
|
|
|
|
|
Vanillylmandelic Acid (VMA) Test |
2-7 mg/24 hours |
|
|
VAP Cholesterol Test |
|
|
|
|
|
|
|
Varicella-Zoster Virus (VZV) Antibody Test |
IgM |
Negative |
|
|
IgG |
|
|
|
Vaccinated: positive (> or =1.1 AI) |
Unvaccinated: negative (< or =0.8 AI) |
|
|
|
|
|
Venogram Test |
|
|
|
Visual Evoked Potential (VEP) Test |
|
|
|
Vitamin A (Retinol) Test |
32.5-78.0 mcg/dL |
|
|
|
|
|
|
Vitamin B12 Assay Test |
180-914 ng/L |
|
|
Vitamin D Test |
|
|
|
Vitamin E (Alpha- Tocopherol) Test |
5.5-17.0 mg/L |
|
|
|
|
|
|
Vitamin K Test |
0.2-3.2 ng/mL |
|
|
|
|
|
|
VLDL Cholesterol Test |
2 - 30 mg/dl |
|
|
Von Willebrand Panel Test |
|
|
|
Warfarin Sensitivity Test |
|
|
|
West Nile Virus Test |
|
|
|
White Blood Cell Count (WBC) Test |
3,500 to 10,500 cells/mcL |
|
|
Widal Test |
|
|
|
Wound Culture (Aerobic/Anaerobic) |
|
|
|
X-ray (digital) |
|
|
|
Zika Virus Test |
|
|
|
Zinc Protoporphyrin (ZPP) Test |
|
|
|
|
|
|
|